Scancell has linked iSCIB1+ to a 69% response rate in advanced melanoma, lead | Scancell has linked iSCIB1+ to a 69% response ...

SCOPE is testing administration of intramuscular SCIB1 and intradermal iSCIB1+, which codes for various melanoma antigens ...

Following the Phase II faceoff between two of Scancell’s lead melanoma immunotherapy candidates, the biotech has selected ...

SCOPE trial of SCIB1/iSCIB1+ plus standard of care shows excellent results encompassing efficacy, durability, immune responses and safety Overall response rate for iSCIB1+ was 69% for target HLA type ...

Scancell Holdings, the developer of Immunobody and Moditope active immunotherapies to treat cancer, has announced further positive data from the ongoing Phase II SCOPE trial of SCIB1/iSCIB1+ ...

Datafeed and UK data supplied by NBTrader and Digital Look. While London South East do their best to maintain the high quality of the information displayed on this site, we cannot ...

Scancell’s CEO Lindy Durrant said: “Securing long-term supply for the PharmaJet Stratis Needle-free Injection System is important to allow clinical and commercial development of iSCIB1+.

PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free SCOPE trial surpasses its first milestone with ...

PharmaJet and Scancell agreement builds on PharmaJet's strategy to be the best-in-class delivery system for novel DNA and RNA cancer immunotherapies.

Scancell Holdings has successfully raised approximately £11.3 million through a significantly oversubscribed retail offer and capital raise, priced at 10.5 pence per share.

Scancell is currently conducting a Phase I clinical trial utilising its SCIB1 vaccine which is being developed for the treatment of melanoma. SCIB1 is a novel DNA vaccine which is also being ...

After more than two decades of working together, Genmab A/S has entered a new licensing agreement with Scancell Holdings plc to gain the exclusive rights to develop and commercialize an anti-glycan ...